EGFR and neoplasm: The availability of sTN58, in conjunction with highly effective anti-EGFR and anti-PDGFRβ aptamers, which we have validated for TNBC targeting and recently used to generate bispecific aptamer-decorated, light-triggered nanoparticles targeting both tumor and stromal cells [18], offers promising potential for developing multi-targeted therapeutic nanosystems.